From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Lung Cancers With Rare EGFR Mutations Being Tackled by Novel Agents

Last Updated: Wednesday, June 16, 2021

Next-generation inhibitors of epidermal growth factor receptor (EGFR) exon 20 insertion mutations showed promise in patients with advanced non–small cell lung cancer (NSCLC) in early-phase trials presented during the International Association Society for Lung Cancer 2020 World Conference on Lung Cancer in Singapore, which was held virtually in January 2021.

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement